Zhi Tong Cai Jing·2025-08-19 05:54Core Viewpoint - The report from CMB International indicates an upward revision of Kingsray Biotechnology's (01548) revenue forecast for 2025-2027 by 1-5%, while lowering the net profit forecast for 2025 due to significant net losses in the first half of 2025 [1] Group 1: Financial Performance - The group's performance for the first half of 2025 met expectations, with revenue from continuing operations increasing by 82% to $519 million [1] - Adjusted net profit surged by 510% to $178 million [1] Group 2: Business Segment Outlook - The group has raised its revenue growth guidance for the life sciences segment for the full year to 13-15%, with an expected growth rate of 15-18% for the second half of the year [1] Group 3: Valuation and Rating - The SOTP model has been rolled forward to 2026, maintaining the target valuation multiples for each business segment [1] - The target price remains at HKD 28.75, with a "Buy" rating retained [1]